Darmstadt, Germany

Frank Zenke

This inventor holds 35 USPTO granted patents and 9 published patent applications, plus 18 CIPO patents and 27 EPO patents, primarily in Cancer Therapeutics. Top assignees: Merck Patent Gmbh, Merck Patent Gesellschaft MIT Beschrankter Haftung. Active years: 2009-2026.

USPTO Granted Patents = 35 

% Patents Active = 37.1

 

 

Average Co-Inventor Count = 4.8

ph-index = 7

Forward Citations = 198(Granted Patents)


Company Filing History:


Years Active: 2009-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
DNA Alkylating Agents
ATR Inhibitors
MetAP-2 Inhibitors
Kinase Inhibitors
PD-1 Antagonist
Cyclic Amides
Pyrrolidinones
Benzimidazole Derivatives
Oxindoles
Heterocyclic Compounds
Pyrazoloquinolines
Heteroarylaminoquinolines
35 patents (USPTO):Explore Patents

Title: The Innovative Journey of Frank Zenke

Introduction: Frank Zenke, a pioneering inventor hailing from Darmstadt, Germany, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Frank Zenke's latest patents include advancements in renewable energy technologies, smart home systems, and medical devices, showcasing his diverse range of expertise and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Frank Zenke has established himself as a leading figure in the field of innovation, holding numerous patents and receiving recognition for his impactful inventions.

Collaborations: Throughout his career, Frank Zenke has collaborated with top research institutions, leading companies, and talented individuals to bring his ideas to life and push the boundaries of technological innovation.

Conclusion: Frank Zenke's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a visionary inventor, inspiring the next generation of innovators to think boldly and push the limits of what is possible.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…